Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire) - Mar 5, 2024 - "In 2024 the Company plans to accomplish the following key business objectives: Present interim safety and feasibility data from the ReSPECT-LM trial at the SNO/ASCO CNS Cancer Conference in August 2024; Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose; Present complete ReSPECT-LM Phase 1 data at the SNO Annual Meeting in November 2024; Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024."
P1 data • Trial status • CNS Tumor • Oncology • Solid Tumor
|